Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes

    ... therapies such as donor lymphocyte infusion and azacitidine . Bone Marrow Diseases:  ...

    Research Article last updated 09/24/2014 - 10:46am.

  2. An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

    ... to evaluate the efficacy and safety of pevonedistat plus azacitidine versus single-agent azacitidine in participants with higher-risk myelodysplastic syndromes, ...

    Clinical Trial last updated 04/28/2016 - 1:58pm.

  3. Myelodysplastic syndromes: health care management considerations.

    ... two hypomethylating agents approved for this indication-- azacitidine and decitabine --in terms of proven effectiveness, safe ... only with continued discussion and study. The therapies azacitidine and decitabine may offer a good model for decision making to drive ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. How we treat higher-risk myelodysplastic syndromes

    ... Standard therapies include the hypomethylating agents azacitidine and decitabine , which should be administered for a ...

    Research Article last updated 01/08/2014 - 8:57am.

  5. Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?

    ... At diagnosis, 86% of MDS patients are ≥60 years. Azacitidine , the only drug that prolongs life in high-risk (HR)-MDS ...

    Research Article last updated 10/22/2013 - 3:12pm.

  6. Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes.

    ... therapies include the DNA methyltransferase inhibitors azacitidine and decitabine . Recently, azacitidine demonstrated the ability to extend survival by as much as 74% ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Myelodysplastic syndromes: What do hospitalists need to know?

    ... prediction and risk-adapted therapy. The addition of azacitidine , decitabine , and lenalidomide to ...

    Research Article last updated 06/20/2013 - 10:59am.

  8. Prognostic role of immunohistochemical analysis of 5mc in Myelodysplastic Syndromes.

    ... has demonstrated clinical effectiveness; the drugs azacitidine and decitabine have been approved for the treatment of ...

    Research Article last updated 06/20/2013 - 10:57am.

  9. Myelodysplastic syndromes and autoimmune diseases-Case series and review of literature.

    ... four cases showed improvement in AD after 5- azacitidine treatment. The mechanism(s) of the association between AD and ...

    Research Article last updated 06/20/2013 - 10:40am.

  10. Can hypomethylating agents provide a platform for curative therapy in myelodysplastic syndromes?

    ... The hypomethylating agents (HMAs) azacitidine and decitabine have changed the treatment landscape of ...

    Research Article last updated 01/03/2013 - 9:48am.